Skip to main content
Erschienen in: Drugs & Aging 5/2019

02.04.2019 | Letter to the editor

The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People

verfasst von: Farhad Pazan, Christel Weiss, Martin Wehling, FORTA

Erschienen in: Drugs & Aging | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Excerpt

Multimorbidity and widespread use of clinical guidelines are the main causes for highly prevalent polypharmacy in older people [1, 2]. Polypharmacy has been identified as a major risk factor for inappropriate drug treatment and adverse drug events in older patients [35], and is even associated with increased mortality [6, 7]. However, the use of multiple drugs to treat serious medical conditions is often vital, but should be differentiated into appropriate/beneficial or problematic applications by the critical review of medication schemes. Several listing approaches and tools have been developed to assist prescribers in choosing the appropriate drugs for their patients. The majority of these approaches (e.g., Beers criteria [8]) are drug-oriented listing approaches (DOLA) [9] and mostly focus on what not to prescribe in older patients. Their impact on relevant clinical outcomes (e.g., mortality or hospitalization) is still unclear [10], with the majority of randomized clinical trials failing to demonstrate improvement of clinical endpoints [9]. In contrast, a few listing approaches (e.g., the FORTA [Fit fOR The Aged] List) are patient-in-focus listing approaches (PILA); they recommend both what to do and what not to do, requiring intricate medical knowledge about patients. For PILA, the majority of randomized trials have been clinically successful [9]. …
Literatur
1.
Zurück zum Zitat Mc Namara KP, Breken BD, Alzubaidi HAT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia. Age Ageing. 2017;46:291–9.PubMed Mc Namara KP, Breken BD, Alzubaidi HAT, et al. Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia. Age Ageing. 2017;46:291–9.PubMed
4.
Zurück zum Zitat Wauters M, Elseviers M, Vaes B, et al. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016;82:1382–92.CrossRefPubMedPubMedCentral Wauters M, Elseviers M, Vaes B, et al. Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old. Br J Clin Pharmacol. 2016;82:1382–92.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39:109–16.CrossRefPubMed Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39:109–16.CrossRefPubMed
6.
Zurück zum Zitat Morley JE. Inappropriate drug prescribing and polypharmacy are major causes of poor outcomes in long-term care. J Am Med Dir Assoc. 2014;15:780–2.CrossRefPubMed Morley JE. Inappropriate drug prescribing and polypharmacy are major causes of poor outcomes in long-term care. J Am Med Dir Assoc. 2014;15:780–2.CrossRefPubMed
7.
Zurück zum Zitat Leelakanok N, Holcombe AL, Lund BC, et al. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc. 2017;57:729–38.CrossRef Leelakanok N, Holcombe AL, Lund BC, et al. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc. 2017;57:729–38.CrossRef
8.
Zurück zum Zitat American Geriatrics Society (2012) Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;2012(60):616–31.CrossRef American Geriatrics Society (2012) Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;2012(60):616–31.CrossRef
10.
Zurück zum Zitat Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71:1415–27.CrossRefPubMed Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71:1415–27.CrossRefPubMed
11.
Zurück zum Zitat Kuhn-Thiel AM, Weiss C, Wehling M, The FORTA Authors/Expert Panel Members. Consensus validation of the FORTA (Fit fOR The Aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131–40.CrossRefPubMed Kuhn-Thiel AM, Weiss C, Wehling M, The FORTA Authors/Expert Panel Members. Consensus validation of the FORTA (Fit fOR The Aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131–40.CrossRefPubMed
13.
Zurück zum Zitat Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: Fit fOR The Aged. J Am Geriatr Soc. 2009;57:560–1.CrossRefPubMed Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: Fit fOR The Aged. J Am Geriatr Soc. 2009;57:560–1.CrossRefPubMed
14.
Zurück zum Zitat Michalek C, Wehling M, Schlitzer J, Frohnhofen H. Effects of “Fit fOR The Aged” (FORTA) on pharmacotherapy and clinical endpoints—a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70:1261–7.CrossRefPubMed Michalek C, Wehling M, Schlitzer J, Frohnhofen H. Effects of “Fit fOR The Aged” (FORTA) on pharmacotherapy and clinical endpoints—a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70:1261–7.CrossRefPubMed
15.
Zurück zum Zitat Wehling M, Burkhardt H, Kuhn-Thiel AM, Pazan F, Throm C, Weiss C, Frohnhofen H. VALFORTA—a randomized trial to validate the FORTA (“Fit fOR The Aged”) classification. Age Ageing. 2016;45:262–7.CrossRefPubMed Wehling M, Burkhardt H, Kuhn-Thiel AM, Pazan F, Throm C, Weiss C, Frohnhofen H. VALFORTA—a randomized trial to validate the FORTA (“Fit fOR The Aged”) classification. Age Ageing. 2016;45:262–7.CrossRefPubMed
16.
Zurück zum Zitat Pazan F, Burkhardt H, Frohnhofen H, Weiss C, Throm C, Kuhn-Thiel A, Wehling M. Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. Eur J Clin Pharmacol. 2018;74:339–47.CrossRefPubMed Pazan F, Burkhardt H, Frohnhofen H, Weiss C, Throm C, Kuhn-Thiel A, Wehling M. Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. Eur J Clin Pharmacol. 2018;74:339–47.CrossRefPubMed
17.
Zurück zum Zitat Wehling M. How to use the FORTA (“Fit fOR The Aged”) list to improve pharmacotherapy in the elderly. Drug Res. 2016;66:57–62. Wehling M. How to use the FORTA (“Fit fOR The Aged”) list to improve pharmacotherapy in the elderly. Drug Res. 2016;66:57–62.
Metadaten
Titel
The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People
verfasst von
Farhad Pazan
Christel Weiss
Martin Wehling
FORTA
Publikationsdatum
02.04.2019
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 5/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00669-6

Weitere Artikel der Ausgabe 5/2019

Drugs & Aging 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.